View Cart  

Unapproved Ophthalmic Drugs Draw Warnings for Akorn, Bausch + Lomb

A A
Akorn and Bausch + Lomb (B+L) have received warning letters from the FDA for marketing unapproved ophthalmic drugs containing pilocarpine hydrochloride at various strengths.

To View This Article:

Login

Subscribe To Drug Industry Daily